Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

Rhea-AI Summary

Mirati Therapeutics (Nasdaq: MRTX) has successfully closed an underwritten public offering of 4,985,706 shares of common stock at $202.00 per share. The offering included 4,585,706 shares from Mirati and 400,000 from a selling stockholder, with gross proceeds approximating $926.3 million. This includes the complete exercise of underwriters' options for additional shares. The funds raised will likely support the company's ongoing development of its cancer therapeutics pipeline, including adagrasib and sitravatinib.

Positive

• Gross proceeds of approximately $926.3 million from the public offering.
• Funding will support the development of therapeutic programs targeting cancer.

Negative

• Share dilution concerns due to additional shares being issued.

SAN DIEGO, Oct. 30, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the closing of its previously announced underwritten public offering of 4,985,706 shares of its common stock at a public offering price of $202.00 per share, which consists of 4,585,706 shares sold by Mirati and 400,000 shares sold by a selling stockholder. This includes the exercise in full by the underwriters of their option to purchase up to 625,309 additional shares of common stock from Mirati and up to 25,000 additional shares of common stock from the selling stockholder. The aggregate gross proceeds to Mirati from this offering were approximately $926.3 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati. 

Goldman Sachs & Co. LLC, SVB Leerink LLC, Cowen and Company, LLC and Evercore Group, L.L.C.  acted as joint book-running managers in the offering. Barclays Capital Inc., Credit Suisse Securities (USA) LLC and Piper Sandler & Co. also acted as book-running managers in the offering.

The shares of common stock described above were offered by Mirati pursuant to a shelf registration statement filed by Mirati with the Securities and Exchange Commission ("SEC") that became automatically effective upon filing. A final prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC and are available on the SEC's website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; or from SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at (800) 808-7525, ext. 6132, or by email at syndicate@svbleerink.com; or from Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (833) 297-2926, or by email at PostSaleManualRequests@broadridge.com; or from Evercore Group, L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, or by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Mirati Therapeutics

Mirati Therapeutics is a San Diego-based late-stage biotechnology company relentlessly focused on translating drug discovery and research into new treatments for patients by advancing and delivering novel therapeutics that target the genetic and immunologic drivers of cancer. Mirati is advancing a novel pipeline to treat large patient populations across multiple programs and tumor types, including two programs, adagrasib and sitravatinib, in registration-enabling studies to treat non-small cell lung cancer (NSCLC).

Adagrasib is an investigational small molecule and selective KRAS G12C inhibitor in clinical development as a monotherapy and in combinations. MRTX1133 is an investigational small molecule and selective KRAS G12D inhibitor in preclinical development.

Sitravatinib is an investigational spectrum-selective inhibitor of receptor tyrosine kinases (RTK) designed to enhance immune responses through the inhibition of immunosuppressive signaling. Sitravatinib is being evaluated in multiple clinical trials to treat patients who are refractory to prior immune checkpoint inhibitor therapy, including a Phase 3 trial of sitravatinib in combination with nivolumab in NSCLC.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/mirati-therapeutics-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-301164148.html

SOURCE Mirati Therapeutics, Inc.

FAQ

What is the public offering price for Mirati Therapeutics (MRTX) shares?

The public offering price for Mirati Therapeutics shares was $202.00 per share.

How much money did Mirati Therapeutics raise from the stock offering?

Mirati Therapeutics raised approximately $926.3 million from the stock offering.

What will Mirati Therapeutics use the proceeds from the offering for?

The proceeds from the offering are expected to support the development of their drug pipeline targeting cancer treatments.

Who managed the Mirati Therapeutics public offering?

Goldman Sachs & Co. LLC, SVB Leerink LLC, Cowen and Company, LLC, and Evercore Group, L.L.C. acted as joint book-running managers for the offering.

What are the risks associated with the stock offering of Mirati Therapeutics?

The primary risk associated with the offering is share dilution for existing shareholders due to the increase in the number of outstanding shares.